Precision Medicine in Osteosarcoma: MATCH Trial and Beyond.

ABSTRACT: Osteosarcoma (OS) is a rare bone malignant tumour with a poor prognosis in the case of recurrence. So far, there is no agreement on the best systemic therapy for relapsed OS. The availability of next generation sequencing techniques has recently revolutionized clinical research. The sequencing of the tumour and its matched normal counterpart has the potential to reveal a wide landscape of genetic alterations with significant implications for clinical practice. The knowledge that the genomic profile of a patient's tumour can be precisely mapped and matched to a targeted therapy in real time has improved the development of precision medicine trials (PMTs). PMTs aiming at determining the effectiveness of targeted therapies could be advantageous for patients with a tumour refractory to standar

SUBMITTER: Tirtei E 

PROVIDER: S-EPMC7911557 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature